Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 30 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.04 Insider Own58.17% Shs Outstand11.63M Perf Week-11.52%
Market Cap5.99M Forward P/E- EPS next Y- Insider Trans1.75% Shs Float5.45M Perf Month4.31%
Income-12.22M PEG- EPS next Q-0.07 Inst Own8.49% Short Float / Ratio0.45% / 0.49 Perf Quarter-40.26%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Interest0.02M Perf Half Y-67.49%
Book/sh0.67 P/B0.68 EPS next Y- ROA-248.00% Target Price3.00 Perf Year-
Cash/sh0.70 P/C0.66 EPS next 5Y- ROE-323.09% 52W Range0.40 - 6.75 Perf YTD-88.83%
Dividend- P/FCF- EPS past 5Y- ROI-139.72% 52W High-93.19% Beta-
Dividend %- Quick Ratio16.46 Sales past 5Y- Gross Margin- 52W Low16.46% ATR0.07
Employees3 Current Ratio16.46 Sales Q/Q- Oper. Margin0.00% RSI (14)42.96 Volatility15.31% 14.18%
OptionableNo Debt/Eq0.00 EPS Q/Q9.75% Profit Margin- Rel Volume0.53 Prev Close0.47
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume50.26K Price0.46
Recom1.00 SMA20-0.99% SMA50-16.71% SMA200-59.89% Volume26,514 Change-1.46%
Today 04:15PM
Nov-09-23 09:00AM
Oct-16-23 08:38AM
Oct-09-23 04:15PM
Sep-05-23 08:00AM
08:00AM Loading…
Aug-30-23 08:00AM
Aug-28-23 04:15PM
Aug-10-23 09:00AM
Aug-01-23 09:00AM
Jul-24-23 09:00AM
Jul-14-23 03:02PM
Jul-12-23 03:17PM
Jun-28-23 06:23AM
Jun-01-23 09:00AM
May-10-23 09:00AM
04:30PM Loading…
May-09-23 04:30PM
Mar-30-23 09:00AM
Mar-09-23 09:00AM
Feb-08-23 09:00AM
Feb-06-23 09:00AM
Feb-01-23 09:00AM
Jan-24-23 02:11PM
Jan-23-23 11:39AM
Jan-20-23 09:31AM
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham on January 25, 2022 and is headquartered in Ponte Vedra, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MURPHY JOHN RAYMONDDirectorOct 05Buy0.692,6691,842614,792Oct 06 05:32 PM
MURPHY JOHN RAYMONDDirectorOct 04Buy0.7017,33112,132612,123Oct 06 05:32 PM
Pham Quang XCEO and ChairmanSep 05Buy0.9040,00036,1883,410,000Sep 06 03:28 PM
Pham Quang XCEO and ChairmanSep 01Buy0.9170,00063,9453,370,000Sep 05 06:05 AM
MURPHY JOHN RAYMONDDirectorMar 21Buy1.3910,00013,900594,792Mar 22 04:01 PM
MURPHY JOHN RAYMONDDirectorMar 16Buy1.6720,00033,398574,792Mar 16 05:27 PM